181 related articles for article (PubMed ID: 26299336)
1. How medical choices influence quality of life of women carrying a BRCA mutation.
Harmsen MG; Hermens RP; Prins JB; Hoogerbrugge N; de Hullu JA
Crit Rev Oncol Hematol; 2015 Dec; 96(3):555-68. PubMed ID: 26299336
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
[TBL] [Abstract][Full Text] [Related]
4. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
5. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
Finch A; Evans G; Narod SA
Womens Health (Lond); 2012 Sep; 8(5):543-55. PubMed ID: 22934728
[TBL] [Abstract][Full Text] [Related]
6. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?
Loizzi V; Dellino M; Cerbone M; Arezzo F; Chiariello G; Lepera A; Cazzato G; Cascardi E; Damiani GR; Cicinelli E; Cormio G
Hormones (Athens); 2023 Mar; 22(1):19-23. PubMed ID: 36637775
[TBL] [Abstract][Full Text] [Related]
8. [Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer].
Breda AS; Blaakær J
Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294198
[TBL] [Abstract][Full Text] [Related]
9. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
[TBL] [Abstract][Full Text] [Related]
10. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
11. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.
Finch A; Narod SA
Maturitas; 2011 Nov; 70(3):261-5. PubMed ID: 21893388
[TBL] [Abstract][Full Text] [Related]
12. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
[TBL] [Abstract][Full Text] [Related]
13. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
Ludwig KK; Neuner J; Butler A; Geurts JL; Kong AL
Am J Surg; 2016 Oct; 212(4):660-669. PubMed ID: 27649974
[TBL] [Abstract][Full Text] [Related]
14. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
[TBL] [Abstract][Full Text] [Related]
15. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
16. BRCA mutation genetic testing implications in the United States.
Bayraktar S; Arun B
Breast; 2017 Feb; 31():224-232. PubMed ID: 27931006
[TBL] [Abstract][Full Text] [Related]
17. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
[TBL] [Abstract][Full Text] [Related]
18. Risk reduction works for BRCA mutation carriers--with heavy costs.
Vanchieri C
J Natl Cancer Inst; 2005 Jul; 97(14):1032-3. PubMed ID: 16030299
[No Abstract] [Full Text] [Related]
19. Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.
Silva Filho ALD; Carvalho GM; Sena LC; Gomes LPG; Valério MFH; Martins RIL; Cândido EB
Rev Assoc Med Bras (1992); 2020 Aug; 66(8):1134-1138. PubMed ID: 32935810
[TBL] [Abstract][Full Text] [Related]
20. [Satisfaction and overall quality of life in BRCA positive women after prophylactic surgeries].
Šašková P; Pavlišta D; Dostálek L
Rozhl Chir; 2017; 96(8):328-333. PubMed ID: 29058922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]